Company news

Nexalis Therapeutics Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Sep26 Appendix 4C Cash Flow Report

October 29, 2026

Sep26 Appendix 4C Cash Flow Report

October 29, 2026

Sep26 Quarterly Activities Report

October 29, 2026

Sep26 Quarterly Activities Report

October 29, 2026

Proposed issue of securities - NX1

October 29, 2026

Notification of cessation of securities - NX1

October 29, 2026

Change of Director's Interest Notice - Darryl Davies

October 5, 2026

Final Director's Interest Notice - Sean Williams

October 5, 2026

Initial Director's Interest Notice - Niv Dagan

October 5, 2026

Chair Appointment/Resignation

October 1, 2026

Removal of draft wording in the directors report HY accounts

September 1, 2026

Half Yearly Report and Accounts

August 31, 2026

Jun26 Appendix 4C Cash Flow Report

July 30, 2026

Jun26 Quarterly Activities Report

July 30, 2026

Change in substantial holding

July 29, 2026

Update on Funding Facility and Clinical Program

July 5, 2026

Binding Letter of Intent to replace existing $53m facility

May 27, 2026

Suspension from Quotation

May 25, 2026

Mar26 Appendix 4C Cash Flow Report

April 30, 2026

Significant Milestone - First Patient Screened IRX-211 Ph2

April 20, 2026

First patient dosed in IRX-616a Phase 1 trial

March 18, 2026

First eligible participant screened - phase 1 IRX-616a study

March 4, 2026

Preliminary Final Report

February 27, 2026

Dec25 Quarterly Activities Report

January 29, 2026

Dec25 Appendix 4C Cash Flow Report

January 29, 2026

IRX Overview Presentation - SRX-25 and Nexalis

December 9, 2025

$12.6m Facility to Drive SRX-25 Development

December 3, 2025

Prospectus - Non-Renounceable Rights Issue Offer

November 26, 2025

Drug Development Pipeline Bolstered and Capital Raise

November 26, 2025

Trading Halt

November 23, 2025

Sep25 Quarterly Activities Report

October 31, 2025

Sep25 Appendix 4C Cash Flow Report

October 31, 2025

Half Yearly Report and Accounts

August 25, 2025

Jun25 Quarterly Activities Report

July 22, 2025

Jun25 Appendix 4C Cash Flow Report

July 22, 2025

Mar25 Quarterly Activities Report

April 28, 2025

Mar25 Appendix 4C Cash Flow Report

April 28, 2025

IRX Completes First Drawdown Under Clendon Facility

April 24, 2025

IRX-616a Study Order Executed to Commence Phase 1

April 17, 2025

Study Order Executed for Phase 2 BTcP Trial

March 13, 2025

Updated Dec24 Quarterly Activities Report

January 24, 2025

Dec24 Quarterly Activities Report

January 23, 2025

Dec24 Appendix 4C Cash Flow Report

January 23, 2025

Shareholder Update

December 19, 2024

Issue of Securities Following General Meeting Approval

December 15, 2024

Ethics Approval for Phase 2 Clinical Trial of IRX-211

November 14, 2024

Sep24 Appendix 4C Cash Flow Report

October 31, 2024

Sep24 Quarterly Activities Report

October 31, 2024

$38.5m Funding to Fully Fund Clinical Development Plans

October 17, 2024

Issue of Shares to CEO in Lieu of Accrued Salary

October 2, 2024

Older news releases →

Decks

The 5 newest of 12 decks. Every deck is listed under its year.